Feature Image

Wall Street Analysts Rank Medical Marijuana, Inc. and AXIM® Biotechnologies Among Top 10 Most Successful Cannabis Companies

High Times Magazine features Medical Marijuana, Inc. and AXIM® Biotechnologies in article titled “10 Largest Marijuana Companies Raking in Huge Profits”.

Both Medical Marijuana, Inc. and AXIM® Biotechnologies received validation of their hard work through 2016 this week when the companies were listed among the top 10 largest cannabis companies by market cap in a report by leading cannabis industry financial experts.

Viridian Capital Advisors, Wall Street analysts focused on the burgeoning cannabis industry, released the latest results of their cannabis stock index, which tracks the movement of publicly traded cannabis companies.

Medical Marijuana, Inc. was listed 6th in the report with a total market cap of $380 million and a year to date increase in stock price of nearly 300 percent. This success came from a year of achievements that set Medical Marijuana, Inc. apart as a proven industry leader.

“With historic, first-ever import approvals for medical cannabis products in Mexico, Columbia and Paraguay, and continued growth of our Brazil business, 2016 was a very exciting year for the Company,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus in response to the news. “We applaud the news media for covering developments on the financial side, and for savvy investors who are starting to look into the fastest-growing sector in the US.”

Recreational and Medical Marijuana

Medical Marijuana, Inc was preceded on the list by its investment company AXIM® Biotechnologies, which was ranked 5th with a market cap of $401 million. At one point late in 2016, AXIM®’s stock soared over 2000 percent on the announcement the company secured the funding necessary to pursue clinical trials on nearly a dozen unique treatments developed by the company.

Viridian’s cannabis stock index increased in value 175 percent this year, demonstrating the incredible potential of the cannabis industry. The value of the cannabis industry has been predicted to reach between $4450 billion by 2020.

Of the ten companies listed, nine of them were biotech/pharmaceutical companies, revealing cannabinoid-based treatments to be a lucrative segment of the growing cannabis market. Companies like AXIM® Biotechnologies and Kannalife™ Sciences are working to unlock solutions to some of the most difficult to treat conditions that we face, including Alzheimer’s disease, Parkinson’s disease, CTE, multiple sclerosis, and IBS and Crohn’s disease.

Read more about the Medical Marijuana, Inc. portfolio of investment companies on our news feed.

  • January 6, 2017
  • Jeffrey Stamberger